Adam Metwalli, MD
Urology · Washington, DCNPI 1952499253
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Corbin Clinical Resources at 50.3% of the total. Reporting peaked in 2023 at $12,044 and has fallen 91.9% since, to $981 in 2025.
Across 232 payments — averaging $115.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corbin Clinical Resources$14K
- Intuitive Surgical$5K
- Urogen Pharma, Inc.$773
- Olympus Corporation Of The Americas$739
- Johnson & Johnson$696
- Pfizer$667
- plus $5K from 31 others
What the payments were for
- Speaking & faculty fees$13,50050%
- Travel & lodging$2,0178%
- Food & beverage$7,35427%
- Education$3,96015%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corbin Clinical Resources | 5 | $13,500 |
| Intuitive Surgical | 28 | $5,055 |
| Urogen Pharma, Inc. | 14 | $773 |
| Olympus Corporation Of The Americas | 6 | $739 |
| Johnson & Johnson(3 entities) | 27 | $696 |
| Pfizer | 25 | $667 |
| Boston Scientific | 14 | $613 |
| Cook Medical LLC | 10 | $500 |
| Corcept Therapeutics | 13 | $484 |
| Teleflex LLC | 4 | $463 |
| Dendreon Pharmaceuticals LLC | 12 | $446 |
| Astellas Pharma US Inc | 6 | $382 |
| Myovant Sciences Inc. | 20 | $358 |
| United Medical Systems (de), Inc. | 1 | $284 |
| Coloplast | 6 | $269 |
| Angiodynamics, Inc. | 2 | $196 |
| Bayer | 6 | $161 |
| Procept Biorobotics Corporation | 1 | $158 |
| EDAP Technomed Inc | 2 | $155 |
| AstraZeneca | 1 | $124 |
| Baxter Healthcare | 1 | $122 |
| Sumitomo Pharma America, Inc. | 5 | $118 |
| Convatec Inc. | 4 | $101 |
| Progenics Pharmaceuticals, Inc. | 3 | $86 |
| Conmed Corporation | 1 | $71 |
| Olympus America Inc. | 2 | $54 |
| Ferring Pharmaceuticals Inc. | 3 | $53 |
| Ambu Inc. | 1 | $25 |
| Novartis | 1 | $22 |
| Amgen | 1 | $22 |
| Telix Pharmaceuticals | 1 | $22 |
| Davol Inc. | 1 | $21 |
| 180 Medical, Inc. | 1 | $21 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| AbbVie | 1 | $20 |
| Axonics, Inc. | 1 | $19 |
| Photocure Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$3,000
- Da Vinci Surgical System$1,702
- JELMYTO$291
- XTANDI$249
- PROVENGE$232
- Korlym$225
- ZUSDURI$171
- AquaBeam Robotic System$158
- UroLift$152
- REZUM$135
- Luja Coude$131
- LYNPARZA$124
- TISSEEL$122
- Nanoknife$121
- FIBER DUST$118
- Cook Medical Urology$116
- Barrigel$115
- Erleada$111
- NGage$105
- rezum Generator$103
How this compares
$26,830 in reported general payments places this provider in the 85th percentile of 47 urology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 18 | $18,766 |
| Finasteride | 397 | $5,510 |
| Tamsulosin Hcl | 230 | $3,345 |
| Oxybutynin Chloride ErOxybutynin Chloride | 94 | $2,544 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 18 | $467 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $68 |
| Levofloxacin | 13 | $32 |
| Dexamethasone | 13 | $6 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $118 | $18,76618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 47 urology providers in District of Columbia.
Other urology in Washington
- Armine SmithWashington$58K
- Nathan ShawWashington$54K
- Lambros StamatakisWashington$39K
- Patrick MufarrijWashington$31K
- Ryan HankinsWashington$29K
- Michael WhalenWashington$17K
- Pamela ColemanWashington$14K
- Leslie DeaneWashington$13K
- Jason EngelWashington$12K
- Keith KowalczykWashington$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.